Marivelisse Santiago Cordero

Array ( [id] => 17357086 [patent_doc_number] => 20220017882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 17/312191 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -114 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370346 [patent_doc_number] => 20220025398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => A SCALABLE PLATFORM FOR THE DEVELOPMENT OF CELL-TYPE-SPECIFIC VIRUSES [patent_app_type] => utility [patent_app_number] => 17/311255 [patent_app_country] => US [patent_app_date] => 2019-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428752 [patent_doc_number] => 20220056460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => CRISPR GUIDE-RNA EXPRESSION STRATEGIES FOR MULTIPLEX GENOME ENGINEERING [patent_app_type] => utility [patent_app_number] => 17/299413 [patent_app_country] => US [patent_app_date] => 2019-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19715582 [patent_doc_number] => 12201095 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Animal model of mucopolysaccharidoses type IVA [patent_app_type] => utility [patent_app_number] => 17/293653 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 8772 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426837 [patent_doc_number] => 20220054545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/291963 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314881 [patent_doc_number] => 20210403929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => AN ASPERGILLUS MICROORGANISM CARRYING DISRUPTIONS OF MULTIPLE GENES AND A METHOD OF PRODUCING THEREOF [patent_app_type] => utility [patent_app_number] => 17/289047 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258893 [patent_doc_number] => 20210371878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => INTEIN PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/285356 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27374 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19902617 [patent_doc_number] => 12279600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Genetically modified sterile avians and method for the reconstitution thereof [patent_app_type] => utility [patent_app_number] => 17/282846 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 35 [patent_no_of_words] => 2199 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292545 [patent_doc_number] => 20210388384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => VECTORS [patent_app_type] => utility [patent_app_number] => 17/283833 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334601 [patent_doc_number] => 20220000932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => USE OF EXTRACELLULAR VESICLES IN COMBINATION WITH TISSUE PLASMINOGEN ACTIVATOR AND/OR THROMBECTOMY TO TREAT STROKE [patent_app_type] => utility [patent_app_number] => 17/280794 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19904318 [patent_doc_number] => 12281314 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-22 [patent_title] => Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder [patent_app_type] => utility [patent_app_number] => 17/280369 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 17771 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067554 [patent_doc_number] => 20210269769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => Colostrum Derived Stem Cells, Neural Differentiation, Compositions and Supplements for Enhancing Mammalian Health [patent_app_type] => utility [patent_app_number] => 17/274404 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126538 [patent_doc_number] => 20210301307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => LDLR NEGATIVE PACKAGING CELL LINE FOR THE PRODUCTION OF VSV-G PSEUDOTYPED RETROVIRAL VECTOR PARTICLES OR VIRUS PARTICLES THEREOF [patent_app_type] => utility [patent_app_number] => 17/264763 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17264763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20386800 [patent_doc_number] => 12486519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => In situ gene editing [patent_app_type] => utility [patent_app_number] => 17/269527 [patent_app_country] => US [patent_app_date] => 2019-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 64 [patent_no_of_words] => 18290 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414338 [patent_doc_number] => 12497611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Compositions and methods for high-throughput activation screening to boost T cell effector function [patent_app_type] => utility [patent_app_number] => 17/268928 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 87 [patent_no_of_words] => 31080 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228898 [patent_doc_number] => 20210355454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => SYSTEMS AND METHODS FOR PRODUCING GENE THERAPY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/262271 [patent_app_country] => US [patent_app_date] => 2019-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 131939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -117 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20547662 [patent_doc_number] => 12558435 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Transient inhibition of p53 in gene therapy [patent_app_type] => utility [patent_app_number] => 17/255362 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 26 [patent_no_of_words] => 27114 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19474090 [patent_doc_number] => 12104168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Cell culture medium [patent_app_type] => utility [patent_app_number] => 17/054108 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 5632 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19737246 [patent_doc_number] => 12214055 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Systems and methods for treating hyper-igm syndrome [patent_app_type] => utility [patent_app_number] => 16/758752 [patent_app_country] => US [patent_app_date] => 2018-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 59 [patent_no_of_words] => 37597 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758752 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20646016 [patent_doc_number] => 12600953 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Compositions and method for establishing organoid cultures from cryogenically preserved tissue [patent_app_type] => utility [patent_app_number] => 16/634818 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 4 [patent_no_of_words] => 1211 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 220 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634818 [rel_patent_id] =>[rel_patent_doc_number] =>)